Use of amitriptyline, bupropion and agomelatine in the treatment of non-depressive disorders: a review of mechanisms and therapeutic indications
DOI:
https://doi.org/10.12775/QS.2025.39.58924Keywords
antidepressants, tricyclic antidepressants, SSRI, amitriptyline, bupropion, agomelatineAbstract
Introduction
Antidepressants such as amitriptyline, bupropion and agomelatine are widely used not only in the treatment of depression, but also in other conditions. Their mechanisms of action affect different neurotransmitter systems, allowing their use in the treatment of pain, addiction or sleep disorders. Amitriptyline, which is a tricyclic antidepressant, has strong analgesic effects. Bupropion, a dopamine and norepinephrine reuptake inhibitor, helps in the treatment of addiction and ADHD. Agomelatine, a melatonin receptor agonist, has been shown to regulate diurnal rhythms, making it useful in the treatment of insomnia and other sleep disorders.
Aim of the Study
The aim of this study is to analyse the use of amitriptyline, bupropion and agomelatine in the treatment of conditions other than depression, with a focus on their mechanisms of action and clinical efficacy.
Materials and Methods
An analysis of PubMed papers was conducted using keywords: antidepressants, tricyclic antidepressants, SSRI, amitriptyline, bupropion, agomelatine.
Basic Results
Amitriptyline is highly effective in the treatment of neuropathic pain, migraines and insomnia due to its potent action on serotonin and histamine receptors. Bupropion is used in the treatment of nicotine addiction and ADHD, as it acts on the dopaminergic and noradrenergic systems to improve concentration and impulse control. Agomelatine, as a melatonin receptor agonist, is used to regulate diurnal rhythms, making it helpful in the treatment of sleep disorders and adaptation to time zone changes. Each of these drugs has unique properties that go beyond their primary use in depression.
References
[1] Katzung, B. G., Masters, S. B., & Trevor, A. J. (Eds.). (2012). Farmakologia i farmakoterapia (wyd. 11). Wydawnictwo Medyczne Urban & Partner.
[2] Moraczewski J, Awosika AO, Aedma KK. Tricyclic Antidepressants. 2023 Aug 17. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 32491723.
[3] Naguy A, Badr BHM. Bupropion-myth-busting! CNS Spectr. 2022 Oct;27(5):545-546. doi: 10.1017/S1092852921000365. Epub 2021 Apr 12. PMID: 33843549.
[4] Khan SR, Berendt RT, Ellison CD, Ciavarella AB, Asafu-Adjaye E, Khan MA, Faustino PJ. Bupropion Hydrochloride. Profiles Drug Subst Excip Relat Methodol. 2016;41:1-30. doi: 10.1016/bs.podrm.2015.12.001. Epub 2016 Feb 17. PMID: 26940167.
[5] De Berardis D, Conti CM, Marini S, Ferri F, Iasevoli F, Valchera A, Fornaro M, Cavuto M, Srinivasan V, Perna G, Carano A, Piersanti M, Martinotti G, Di Giannantonio M. Is there a role for agomelatine in the treatment of anxiety disorders?A review of published data. Int J Immunopathol Pharmacol. 2013 Apr-Jun;26(2):299-304. doi: 10.1177/039463201302600203. PMID: 23755745.
[6] George M. Brenner, PhD Craig W. Stevens (2010). “Pharmacology, Third Edition”. Elsevier Inc.
[7] Tour A, Marwaha R. Amitriptyline. 2023 Jul 18. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 30725910.
[8] Zechnich R. Delirium and tricyclic antidepressants. Am J Psychiatry. 1984 Dec;141(12):1642-3. doi: 10.1176/ajp.141.12.1642. PMID: 6507674.
[9] Amitriptylinum VP (2024). Charakterystyka produktu leczniczego.
[10] Ford AC, Wright-Hughes A, Alderson SL, Ow PL, Ridd MJ, Foy R, Bianco G, Bishop FL, Chaddock M, Cook H, Cooper D, Fernandez C, Guthrie EA, Hartley S, Herbert A, Howdon D, Muir DP, Nath T, Newman S, Smith T, Taylor CA, Teasdale EJ, Thornton R, Farrin AJ, Everitt HA; ATLANTIS trialists. Amitriptyline at Low-Dose and Titrated for Irritable Bowel Syndrome as Second-Line Treatment in primary care (ATLANTIS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023 Nov 11;402(10414):1773-1785. doi: 10.1016/S0140-6736(23)01523-4. Epub 2023 Oct 16. PMID: 37858323.
[11] Torrente Castells E, Vázquez Delgado E, Gay Escoda C. Use of amitriptyline for the treatment of chronic tension-type headache. Review of the literature. Med Oral Patol Oral Cir Bucal. 2008 Sep 1;13(9):E567-72. PMID: 18758401.
[12] Ertsey C, Magyar M, Gyüre T, Balogh E, Bozsik G. A tenziós fejfájás és kezelése [Tension type headache and its treatment possibilities]. Ideggyogy Sz. 2019 Jan 30;72(1-2):13-21. Hungarian. doi: 10.18071/isz.72.0013. PMID: 30785242.
[13] Attal N. Pharmacological treatments of neuropathic pain: The latest recommendations. Rev Neurol (Paris). 2019 Jan-Feb;175(1-2):46-50. doi: 10.1016/j.neurol.2018.08.005. Epub 2018 Oct 11. PMID: 30318260.
[14] Trivedi PD, Posani S, Balla N, Sheezan MM, Hussain AS, Xavier R, Popatbhai KM, Mateen MA, Prajjwal P, Marsool Marsool MD. Efficacy of pregabalin, amitriptyline, and gabapentin for neuropathic pain. Bioinformation. 2024 Apr 30;20(4):386-390. doi: 10.6026/973206300200386. PMID: 38854766; PMCID: PMC11161879.
[15] Thompson DF, Brooks KG. Systematic review of topical amitriptyline for the treatment of neuropathic pain. J Clin Pharm Ther. 2015 Oct;40(5):496-503. doi: 10.1111/jcpt.12297. Epub 2015 Jun 7. PMID: 26059975.
[16] Praharaj SK, Arora M. Amitriptyline for clozapine-induced nocturnal enuresis and sialorrhoea. Br J Clin Pharmacol. 2007 Jan;63(1):128-9. doi: 10.1111/j.1365-2125.2006.02748.x. Epub 2006 Aug 30. PMID: 16939528; PMCID: PMC2000705.
[17] Glazener CM, Evans JH, Peto RE. Tricyclic and related drugs for nocturnal enuresis in children. Cochrane Database Syst Rev. 2003;(3):CD002117. doi: 10.1002/14651858.CD002117. Update in: Cochrane Database Syst Rev. 2016 Jan 20;(1):CD002117. doi: 10.1002/14651858.CD002117.pub2. PMID: 12917922.
[18] Cioplean ED, Camburu LR. TRANSITORY CONSECUTIVE ESOTROPIA AFTER AMITRIPTYLINE TREATMENT FOR NOCTURNAL ENURESIS -CASE REPORT. Rom J Ophthalmol. 2015 Apr-Jun;59(2):116-8. PMID: 26978874; PMCID: PMC5712929.
[19] Alhowiti AM, Mirghani HO. Pregabalin and amitriptyline as first-line drugs among patients with painful peripheraldiabetic neuropathy: a systematic review and meta-analysis. Eur Rev Med Pharmacol Sci. 2024 May;28(10):3598-3606. doi: 10.26355/eurrev_202405_36296. PMID: 38856135.
[20] Chang MC, Yang S. Diabetic peripheral neuropathy essentials: a narrative review. Ann Palliat Med. 2023 Mar;12(2):390-398. doi: 10.21037/apm-22-693. Epub 2023 Feb 8. PMID: 36786097.
[21] Huecker MR, Smiley A, Saadabadi A. Bupropion. [Aktualizacja 2024 Sep 2]. W: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Dostępne w: https://www.ncbi.nlm.nih.gov/books/NBK470212/
[22] LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Bupropion. [Aktualizacja 2017 Sep 11]. Dostępne na stronie: https://www.ncbi.nlm.nih.gov/books/NBK548836/
[23] Clark A, Tate B, Urban B, Schroeder R, Gennuso S, Ahmadzadeh S, McGregor D, Girma B, Shekoohi S, Kaye AD. Bupropion Mediated Effects on Depression, Attention Deficit Hyperactivity Disorder, and Smoking Cessation. Health Psychol Res. 2023 Jul 1;11:81043. doi: 10.52965/001c.81043. PMID: 37405312; PMCID: PMC10317506.
[24] Hajizadeh A, Howes S, Theodoulou A, Klemperer E, Hartmann-Boyce J, Livingstone-Banks J, Lindson N. Antidepressants for smoking cessation. Cochrane Database Syst Rev. 2023 May 24;5(5):CD000031. doi: 10.1002/14651858.CD000031.pub6. PMID: 37230961; PMCID: PMC10207863.
[25] Wilens TE, Spencer TJ, Biederman J, Girard K, Doyle R, Prince J, Polisner D, Solhkhah R, Comeau S, Monuteaux MC, Parekh A. A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. Am J Psychiatry. 2001 Feb;158(2):282-8. doi: 10.1176/appi.ajp.158.2.282. PMID: 11156812.
[26] Elmaleh-Sachs A, Schwartz JL, Bramante CT, Nicklas JM, Gudzune KA, Jay M. Obesity Management in Adults: A Review. JAMA. 2023 Nov 28;330(20):2000-2015. doi: 10.1001/jama.2023.19897. PMID: 38015216; PMCID: PMC11325826.
[27] Grilo CM, Lydecker JA, Gueorguieva R. Naltrexone plus bupropion combination medication maintenance treatment for binge-eating disorder following successful acute treatments: randomized double-blind placebo-controlled trial. Psychol Med. 2023 Dec;53(16):7775-7784. doi: 10.1017/S0033291723001800. Epub 2023 Jun 27. PMID: 37366017; PMCID: PMC10751383.
[28] Savino R, Polito AN, Marsala G, Ventriglio A, Di Salvatore M, De Stefano MI, Valenzano A, Marinaccio L, Bellomo A, Cibelli G, Monda M, Monda V, Messina A, Polito R, Carotenuto M, Messina G. Agomelatine: A Potential Multitarget Compound for Neurodevelopmental Disorders. Brain Sci. 2023 Apr 27;13(5):734. doi: 10.3390/brainsci13050734. PMID: 37239206; PMCID: PMC10216109.
[29] Millan MJ. Agomelatine for the treatment of generalized anxiety disorder: focus on its distinctive mechanism of action. Ther Adv Psychopharmacol. 2022 Jun 30;12:20451253221105128. doi: 10.1177/20451253221105128. PMID: 35795687; PMCID: PMC9251978.
[30] Williams WP 3rd, McLin DE 3rd, Dressman MA, Neubauer DN. Comparative Review of Approved Melatonin Agonists for the Treatment of Circadian Rhythm Sleep-Wake Disorders. Pharmacotherapy. 2016 Sep;36(9):1028-41. doi: 10.1002/phar.1822. Epub 2016 Sep 1. PMID: 27500861; PMCID: PMC5108473.
[31] Fahri Aydın E, Güleç M, Oral E, Gökhan Daloğlu A. The Effects of Fluoxetine and Agomelatine on Neurocognitive Functions and Sleep in Patients with Major Depressive Disorder. Psychiatry Clin Psychopharmacol. 2024 Mar 1;34(1):9-18. doi: 10.5152/pcp.2024.22498. PMID: 38883888; PMCID: PMC11177640.
[32] Li HH, Yao XY, Tao S, Sun X, Li PP, Li XX, Liu ZL, Ren C. Serotonin 2 Receptors, Agomelatine, and Behavioral and Psychological Symptoms of Dementia in Alzheimer's Disease. Behav Neurol. 2021 Mar 31;2021:5533827. doi: 10.1155/2021/5533827. PMID: 33859767; PMCID: PMC8026319.
[33] Su Q, Li T, Liu GW, Zhang YL, Guo JH, Wang ZJ, Wu MN, Qi JS. Agomelatine: a potential novel approach for the treatment of memory disorder in neurodegenerative disease. Neural Regen Res. 2023 Apr;18(4):727-733. doi: 10.4103/1673-5374.353479. PMID: 36204828; PMCID: PMC9700086.
[34] Dastan F, Gholizadeh Niari B, Adimi Naghan P, Barati S, Eskandari R. Evaluating the Effects of Agomelatine on Polysomnography Parameters in Patients with Obstructive Sleep Apnea. J Pharm Pharm Sci. 2023;25:418-424. doi: 10.18433/jpps33252. PMID: 36623475.
[35] Moreno-SanJuan S, Puentes-Pardo JD, Casado J, Escudero-Feliu J, Khaldy H, Arnedo J, Carazo Á, León J. Agomelatine, a Melatonin-Derived Drug, as a New Strategy for the Treatment of Colorectal Cancer. Antioxidants (Basel). 2023 Apr 13;12(4):926. doi: 10.3390/antiox12040926. PMID: 37107301; PMCID: PMC10135458.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Piotr Czerniak, Julia Buszek, Michał Medygrał, Przemysław Koszuta, Małgorzata Dydoń-Pikor, Katarzyna Pajdak-Gicala, Maciej Kawecki, Adrianna Antoszewska, Weronika Bargiel, Sylwia Buszek

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 405
Number of citations: 0